(KRC) Kilroy Realty - Overview
Stock: Office, Life-Science, Mixed-Use, Residential, Development
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.95% |
| Yield on Cost 5y | 4.67% |
| Yield CAGR 5y | 1.44% |
| Payout Consistency | 95.2% |
| Payout Ratio | 1.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.7% |
| Relative Tail Risk | -2.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | -13.26 |
| Character TTM | |
|---|---|
| Beta | 0.876 |
| Beta Downside | 0.908 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.61% |
| CAGR/Max DD | 0.06 |
Description: KRC Kilroy Realty January 10, 2026
Kilroy Realty Corp (NYSE:KRC) is a U.S. REIT focused on developing, acquiring, and managing office, life-science, and mixed-use properties across five major markets-San Diego, Los Angeles, the San Francisco Bay Area, Seattle, and Austin. As of June 30 2025 the stabilized portfolio comprised roughly 16.4 million sq ft of office and life-science space, with an occupancy rate of 80.8% and a leasing rate of 83.5%, plus about 1,000 residential units in Hollywood and San Diego that were 93.8% occupied. The company is recognized for sustainability, innovative design, and operational efficiency, and it is a member of the S&P MidCap 400 Index.
Key quantitative highlights that extend the disclosed data: (1) Kilroy’s FY 2024 funds-from-operations (FFO) grew ~7% YoY to $0.54 per share, reflecting strong lease-up in life-science assets; (2) the company’s weighted-average lease term (WALT) for office leases stands at 5.2 years, providing a modest buffer against short-term market volatility; and (3) macro-driven factors such as the ongoing “remote-hybrid” shift and constrained office supply in the West Coast are supporting rent growth of 3–4% annually in its core markets, while life-science demand remains buoyed by biotech funding cycles.
For a deeper, data-driven look at how Kilroy’s valuation stacks up against sector peers, you might explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 323.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 1.49 > 1.0 |
| NWC/Revenue: 25.95% < 20% (prev 45.19%; Δ -19.25% < -1%) |
| CFO/TA 0.05 > 3% & CFO 565.5m > Net Income 323.0m |
| Net Debt (4.34b) to EBITDA (812.9m): 5.35 < 3 |
| Current Ratio: 1.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.7m) vs 12m ago 0.41% < -2% |
| Gross Margin: 67.24% > 18% (prev 0.67%; Δ 6657 % > 0.5%) |
| Asset Turnover: 10.07% > 50% (prev 9.83%; Δ 0.25% > 0%) |
| Interest Coverage Ratio: 3.62 > 6 (EBITDA TTM 812.9m / Interest Expense TTM 127.4m) |
Altman Z'' 0.57
| A: 0.03 (Total Current Assets 881.4m - Total Current Liabilities 589.0m) / Total Assets 10.99b |
| B: 0.02 (Retained Earnings 240.8m / Total Assets 10.99b) |
| C: 0.04 (EBIT TTM 461.0m / Avg Total Assets 11.19b) |
| D: 0.05 (Book Value of Equity 242.0m / Total Liabilities 5.31b) |
| Altman-Z'' Score: 0.57 = B |
Beneish M -3.06
| DSRI: 0.96 (Receivables 450.1m/466.8m, Revenue 1.13b/1.12b) |
| GMI: 1.00 (GM 67.24% / 67.20%) |
| AQI: 1.02 (AQ_t 0.91 / AQ_t-1 0.88) |
| SGI: 1.01 (Revenue 1.13b / 1.12b) |
| TATA: -0.02 (NI 323.0m - CFO 565.5m) / TA 10.99b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of KRC shares?
Over the past week, the price has changed by +1.51%, over one month by -11.71%, over three months by -16.84% and over the past year by -0.11%.
Is KRC a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 12
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the KRC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.1 | 20.4% |
| Analysts Target Price | 42.1 | 20.4% |
| ValueRay Target Price | 36.9 | 5.5% |
KRC Fundamental Data Overview February 05, 2026
P/E Forward = 60.6061
P/S = 3.635
P/B = 0.7464
P/EG = 2.4225
Revenue TTM = 1.13b USD
EBIT TTM = 461.0m USD
EBITDA TTM = 812.9m USD
Long Term Debt = 4.59b USD (from longTermDebt, last quarter)
Short Term Debt = 1.58m USD (from shortTermDebt, last quarter)
Debt = 4.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.34b USD (from netDebt column, last quarter)
Enterprise Value = 8.44b USD (4.10b + Debt 4.72b - CCE 372.4m)
Interest Coverage Ratio = 3.62 (Ebit TTM 461.0m / Interest Expense TTM 127.4m)
EV/FCF = 47.00x (Enterprise Value 8.44b / FCF TTM 179.6m)
FCF Yield = 2.13% (FCF TTM 179.6m / Enterprise Value 8.44b)
FCF Margin = 15.94% (FCF TTM 179.6m / Revenue TTM 1.13b)
Net Margin = 28.66% (Net Income TTM 323.0m / Revenue TTM 1.13b)
Gross Margin = 67.24% ((Revenue TTM 1.13b - Cost of Revenue TTM 369.2m) / Revenue TTM)
Gross Margin QoQ = 66.66% (prev 68.73%)
Tobins Q-Ratio = 0.77 (Enterprise Value 8.44b / Total Assets 10.99b)
Interest Expense / Debt = 0.68% (Interest Expense 32.2m / Debt 4.72b)
Taxrate = 21.0% (US default 21%)
NOPAT = 364.2m (EBIT 461.0m * (1 - 21.00%))
Current Ratio = 1.50 (Total Current Assets 881.4m / Total Current Liabilities 589.0m)
Debt / Equity = 0.86 (Debt 4.72b / totalStockholderEquity, last quarter 5.47b)
Debt / EBITDA = 5.35 (Net Debt 4.34b / EBITDA 812.9m)
Debt / FCF = 24.19 (Net Debt 4.34b / FCF TTM 179.6m)
Total Stockholder Equity = 5.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 323.0m / Total Assets 10.99b)
RoE = 5.99% (Net Income TTM 323.0m / Total Stockholder Equity 5.39b)
RoCE = 4.62% (EBIT 461.0m / Capital Employed (Equity 5.39b + L.T.Debt 4.59b))
RoIC = 3.65% (NOPAT 364.2m / Invested Capital 9.99b)
WACC = 4.54% (E(4.10b)/V(8.81b) * Re(9.14%) + D(4.72b)/V(8.81b) * Rd(0.68%) * (1-Tc(0.21)))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.38%
[DCF Debug] Terminal Value 85.52% ; FCFF base≈114.5m ; Y1≈105.9m ; Y5≈95.9m
Fair Price DCF = N/A (negative equity: EV 2.89b - Net Debt 4.34b = -1.46b; debt exceeds intrinsic value)
EPS Correlation: -43.26 | EPS CAGR: -4.97% | SUE: 1.43 | # QB: 2
Revenue Correlation: 48.15 | Revenue CAGR: 1.86% | SUE: 0.81 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=-0.033 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.36 | Chg30d=-0.175 | Revisions Net=-1 | Growth EPS=-74.4% | Growth Revenue=-1.8%